Bromo-DragonFly

Bromo-DragonFLY, also known as ABDF, is a psychedelic hallucinogenic drug somewhat related to the phenethylamine family. Bromo-DragonFLY is considered an extremely potent hallucinogen, only slightly less potent than LSD with a normal dose in the region of 200μg to 800μg, and it has an extremely long duration of action. It is not illegal anywhere in the world at this time although it may be considered a controlled substance analogue under US and Australian drug laws. Bromo-DragonFLY has a stereocenter and R-(-)-bromo-DragonFLY is the more active stereoisomer.

Pharmacology
The hallucinogenic effect of bromo-DragonFLY is mediated by its full agonistic activity at the 5-HT2A serotonin receptor. Bromo-DragonFLY also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptor. It can sometimes be found on "blotters" (small bits of paper containing the substance) reminiscent of the most commonly found form of LSD, thus making it difficult to identify which substance it is carrying.

History
Bromo-DragonFLY was first synthesized by Matthew A. Parker in the laboratory of David E. Nichols in 1998.